{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:O75923",
      "entity_text" : "Dysferlin",
      "features" : [ {
        "to_base" : "A",
        "site" : 0,
        "feature_type" : "mutation",
        "evidence" : "mutant"
      } ],
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:187",
      "entity_text" : "Ach",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "While these pharmacological findings support the hypothesis that there is a deficit of Ach signaling in Dysferlin mutant mice, they also suggest the intriguing possibility that LGMD2B patients might benefit from AchE.I therapy.",
  "reading_complete" : "2020-08-04T10:22:39Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T10:21:30Z",
  "trigger" : "signaling",
  "evidence" : [ "Ach signaling in Dysferlin" ],
  "pmc_id" : "3828772",
  "score" : 0
}